#ssbet77
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). Treatment with AL002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation. However, AL002 failed to meet the primary endpoint of slowing of Alzheimer's clinical progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR ® -SB), and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints. Similarly, there were no significant effects on Alzheimer's fluid biomarkers favoring AL002, and amyloid PET imaging demonstrated no treatment-related reduction of brain amyloid levels. As previously reported, MRI changes resembling amyloid-related imaging abnormalities (ARIA) and infusion-related reactions were observed in INVOKE-2. The instances of ARIA were primarily seen in participants treated with AL002. "We, at Alector, recognize the importance of advancing therapeutics to treat Alzheimer's disease and remain committed in our mission to develop safe and effective treatments for the millions of people worldwide impacted by neurodegenerative diseases,” said Gary Romano, M.D., Ph.D., Chief Medical Officer at Alector. "With a robust dataset from the INVOKE-2 trial, we plan to further explore TREM2 biology. We extend our deepest gratitude to the dedicated investigators, patients and caregivers who made this important trial possible. We plan to share the results of the trial with the scientific community in the near future in the hopes of contributing to the understanding of AD pathophysiology and advancing effective therapeutics for this terrible disease.” Based upon the results, Alector is stopping the long-term extension study. Alector remains committed to advancing its mechanistically broad and genetically validated drug candidates for the treatment of neurodegenerative diseases. At the core of this effort are the company's progranulin-elevating programs, latozinemab and AL101/GSK4527226, developed in collaboration with GSK. Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in frontotemporal dementia with a progranulin gene mutation is expected in late 2025 or early 2026. PROGRESS-AD, a global Phase 2 clinical trial evaluating AL101/GSK4527226 in early AD, has reached more than one-third of its target enrollment of 282 participants. Alector is also advancing its preclinical candidates aimed at a broad and diverse range of protein and enzyme targets. In addition to advancing its pipeline, the company is continuing to develop its proprietary and versatile blood-brain barrier technology platform, Alector Brain Carrier (ABC). ABC aims to enhance the delivery of therapeutic antibodies, proteins and enzymes, achieve deeper penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. To align resources with these strategic priorities, Alector is reducing its workforce by approximately 17%. By focusing on organizational goals, Alector continues to build upon its core strength in developing novel therapies for neurodegenerative diseases, with the potential to deliver transformative value for patients. As of September 30, 2024, Alector has $457.2 million in cash, cash equivalents, and investments, which the company continues to expect will provide runway through 2026. Alector plans to provide guidance for 2025 during its fourth-quarter and full-year earnings conference call. About INVOKE-2 INVOKE-2 (Clinicaltrials.gov identifier NCT04592874), was a randomized, double-blind, placebo-controlled, dose-ranging, multi-center Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). The trial, conducted at multiple sites across 11 countries, utilized a common close design with up to 96 weeks of randomized treatment, and all participants remained on their assigned regimen until the last participant completed 48 weeks of treatment. This design provided the opportunity to capture more observations for the primary analysis, with data collected at 48, 72, and 96 weeks. Patients were randomized to three dose regimens of AL002, 15mg/kg IV/q4w, 40mg/kg IV/q4w, 60mg/kg IV/q4w, or placebo. About Alector Alector is a clinical-stage biotechnology company that has pioneered immuno-neurology. The company has discovered and is developing a portfolio of mechanistically broad and genetically validated product candidates, including antibodies, protein and enzyme replacement therapies, for neurodegenerative diseases. Supported by biomarkers, Alector's product candidates seek to treat a range of indications, including frontotemporal dementia, Alzheimer's disease, and Parkinson's disease. Alector is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding our business plans, workforce reduction, business strategy, product candidates, planned and ongoing preclinical studies and clinical trials, expected milestones, and expectations of our collaborations. Such statements are subject to numerous risks and uncertainties, including but not limited to risks and uncertainties as set forth in Alector's Quarterly Report on Form 10-Q filed on November 6, 2024, with the Securities and Exchange Commission ("SEC”), as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector's forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law. Alector Contacts: Alector Katie Hogan 202-549-0557 [email protected] 1AB (media) Dan Budwick 973-271-6085 [email protected] Argot Partners (investors) Laura Perry 212-600-1902 [email protected]
Jaylon Johnson isn’t interested in bright spots with the Bears’ skid at 5 games
More PwC partners than usual will take early retirement at the end of this year, marking another shake-up at the firm's UK division since the appointment of a new boss, Marco Amitrano, in Spring. PwC's 1,030 UK partners were informed this week via a voice memo from Amitrano that dozens of partners would take early retirement next month, reported. The cohort of early retirees was larger than usual, though one insider disputed that the numbers involved were "significant," Sky News reported. The Big Four firm appointed 60 new UK partners earlier this year. Senior employees at the Big Four consultancies — Deloitte, EY, KPMG, and PwC, all of which are privately held — can be , and some are offered equity ownership in the business. In addition to salary and bonuses, equity partners traditionally receive a share of annual profits. The jump in partners taking early retirement follows a series of changes following Amitrano's elevation to senior partner for the UK and Middle East in April. Amitrano has launched an overhaul of operations in the UK, including creating a standalone technology and artificial intelligence unit and merging other parts of the business to create six new teams, reported in October. Almost all the major consulting firms have been grappling with a slowdown in business this year following the end of the pandemic-era rush on advisory services. The firms have been restructuring divisions, laying off employees, and making cuts to limit revenue decline. have been one area targeted for cuts at EY, Deloitte, and PwC. UK partners at PwC took home an average of £862,000 (about $1.1 million) this financial year, 5% less than they did in 2023. PwC, which is the largest of the Big Four by revenue in the UK, is also facing higher taxes per employee after the country's recently elected Labour government increased the rate of national insurance contributions (a tax on earnings) employers must pay. PwC declined to comment. Read the original article on
The popular series Henry Danger will return in a feature-length movie set to premiere on January 17, 2025. The film will stream on Paramount+ and air on Nickelodeon . Premiere Date, Time and Where to Watch The movie will be available on Paramount+ in the United States from Friday, January 17. It will also air on Nickelodeon the same day at 7 p.m. (ET/PT). Paramount+ will release the movie in select international markets. Nickelodeon's international channels will broadcast it later in the year. Also Read: How to win election in red states? The Democrats can learn from this fiery American evangelical pastor Plot and Cast The story follows Henry Danger, played by Jace Norman , as he meets a superfan who wants to join him in fighting crime. The superfan finds a device that opens alternate realities. Henry must work with his best friend Jasper (Sean Ryan Fox) and the superfan to avoid being trapped in another dimension. The film includes original cast members Ella Anderson (Piper Hart), Michael D. Cohen (Schwoz) and Frankie Grande (Frankini). New cast member Glee Dango plays Missy Martin, the superfan. Artificial Intelligence(AI) Mastering C++ Fundamentals with Generative AI: A Hands-On By - Metla Sudha Sekhar, IT Specialist and Developer View Program Strategy Succession Planning Masterclass By - Nigel Penny, Global Strategy Advisor: NSP Strategy Facilitation Ltd. View Program Web Development Advanced C++ Mastery: OOPs and Template Techniques By - Metla Sudha Sekhar, IT Specialist and Developer View Program Office Productivity Zero to Hero in Microsoft Excel: Complete Excel guide 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Office Productivity Microsoft Word Mastery: From Beginner to Expert By - CA Raj K Agrawal, Chartered Accountant View Program Artificial Intelligence(AI) AI and Analytics based Business Strategy By - Tanusree De, Managing Director- Accenture Technology Lead, Trustworthy AI Center of Excellence: ATCI View Program Web Development Intermediate C++ Skills: Master Pointers, Structures and File Stream By - Metla Sudha Sekhar, IT Specialist and Developer View Program Leadership Building Your Winning Startup Team: Key Strategies for Success By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Data Science SQL Server Bootcamp 2024: Transform from Beginner to Pro By - Metla Sudha Sekhar, IT Specialist and Developer View Program Leadership Crafting a Powerful Startup Value Proposition By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Artificial Intelligence(AI) Generative AI for Dynamic Java Web Applications with ChatGPT By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Marketing & Sales Strategies for Startups: From Concept to Conversion By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Leadership Business Storytelling Masterclass By - Ameen Haque, Founder of Storywallahs View Program Office Productivity Advanced Excel Course - Financial Calculations & Excel Made Easy By - Anirudh Saraf, Founder- Saraf A & Associates, Chartered Accountant View Program Office Productivity Excel Essentials to Expert: Your Complete Guide By - Study At Home, Quality Education Anytime, Anywhere View Program Leadership Boosting Startup Revenue with 6 AI-Powered Sales Automation Techniques By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Office Productivity Mastering Microsoft Office: Word, Excel, PowerPoint, and 365 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Background The Henry Danger series was created by Dan Schneider and Dana Olsen. It debuted on Nickelodeon in July 2014. The show follows Henry Hart, who is chosen by superhero Captain Man as his apprentice. Henry balances his secret life as Kid Danger with his responsibilities as a high school student. Also Read : Billboard ranks Taylor Swift as the No. 2 greatest pop star of the 21st century, who will be No. 1? This singer's name is doing the rounds Production Team Joe Menendez directs the film. Chris Nowak and Jake Farrow wrote the script. Jace Norman, Joe Menendez, Chris Nowak and Jake Farrow serve as executive producers. Frankie Grande performs an original song titled “Smile.” FAQs Where can I watch Henry Danger The Movie ? The movie will stream on Paramount+ and air on Nickelodeon from January 17, 2025. What is the plot of Henry Danger The Movie? The story involves Henry Danger, his best friend Jasper and a superfan navigating alternate dimensions to avoid being trapped. (You can now subscribe to our Economic Times WhatsApp channel )
Shares of artificial intelligence server manufacturer Super Micro, Inc. ($SMCI) continued their volatile run, and on Wednesday, the stock bucked the broader market downturn and traded firmly in positive territory. As of 1:56 p.m. ET, Super Micro stock climbed 2.09% to $35.15, although on below-average volume, potentially due to typical thin pre-holiday trade. Incidentally, the Invesco QQQ Trust ($QQQ), an exchange-traded fund that tracks the Nasdaq 100 Index, was down about 0.80% due to a sell-off in the semiconductor space. After delisting fears abated, Super Micro shares were on the mend, moving from a bottom of $17.25 on Nov. 15 to as high as $39.23 this Monday. On Wednesday, the stock may have received a shot in the arm from twin catalysts. Computer and peripherals manufacturer Dell Technologies, Inc.’s ($DELL) third-quarter results showed AI server sales was strong at $2.9 billion, with orders at a record of $3.6 billion. This in turn is positive for Super Micro, which counts Nvidia Corp. ($NVDA) among its customers. Also, in a 8-K filing with the SEC on Tuesday, Super Micro said it prepaid in full and closed out loans agreements with Cathay Bank and Bank of America on Nov.20. The filing, however, was scant in details and did not reveal the terms of the prepayment or the reasons thereof. The development should allay investors’ concern about cash runway as the company slowly extricates itself from the accounting mess that followed the resignation by Ernst & Young as its auditor in October, citing concerns about governance, transparency and internal control over financial reporting. Since then, the company has appointed a new auditor and also managed to avoid delisting from the Nasdaq exchange by submitting a compliance plan with regard to late-filing of its fiscal-year 2024 annual report and the quarterly report for the first quarter that ended in Sept. 2024. Super Micro stock is up 21% for the year-to-date period. On Stocktwits, retail sentiment remained ‘bullish’ (63/100), albeit message activity remained muted at ‘normal’ levels. A user on the platform suggested follow-on buying materially as shorts are forced to cover. About 15% of the outstanding shares are held short, according to Yahoo Finance data.NoneM&T Bank director John Barnes sells $4.35 million in stockAnimation Guild Reaches Tentative Deal With Studios After Bargaining Over AI Guardrails and More
Leading Romanian presidential candidate spells trouble for NATO and Ukraine
CHARLOTTE AMALIE, Virgin Islands (AP) — Trey Autry scored 16 points off of the bench to help lead George Washington over Illinois State 72-64 on Monday night to claim a fifth-place finish at the Paradise Jam tournament in the Virgin Islands. Autry had five rebounds for the Revolutionaries (6-1). Gerald Drumgoole Jr. scored 16 points while going 4 of 9 from the floor, including 2 for 5 from 3-point range, and 6 for 7 from the line. Darren Buchanan Jr. shot 3 of 11 from the field and 9 for 11 from the line to finish with 15 points, while adding 10 rebounds. The Redbirds (4-3) were led by Chase Walker, who posted 18 points and two steals. Johnny Kinziger added 16 points for Illinois State. Dalton Banks also had 13 points, six rebounds and two steals. Autry scored seven points in the first half and George Washington went into the break trailing 29-27. NEXT UP George Washington's next game is Friday against VMI at home, and Illinois State visits Belmont on Wednesday. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .AP Sports SummaryBrief at 6:57 p.m. EST
A Missouri judge says a law banning surgery, medications for transgender minors is constitutionalNone